Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Share-based Compensation: 2018-2024

Historic Share-based Compensation for Arcutis Biotherapeutics (ARQT) over the last 7 years, with Dec 2024 value amounting to $41.7 million.

  • Arcutis Biotherapeutics' Share-based Compensation rose 2.59% to $10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.7 million, marking a year-over-year decrease of 3.40%. This contributed to the annual value of $41.7 million for FY2024, which is 7.52% up from last year.
  • Latest data reveals that Arcutis Biotherapeutics reported Share-based Compensation of $41.7 million as of FY2024, which was up 7.52% from $38.8 million recorded in FY2023.
  • In the past 5 years, Arcutis Biotherapeutics' Share-based Compensation registered a high of $41.7 million during FY2024, and its lowest value of $7.9 million during FY2020.
  • Over the past 3 years, Arcutis Biotherapeutics' median Share-based Compensation value was $38.8 million (recorded in 2023), while the average stood at $37.7 million.
  • Data for Arcutis Biotherapeutics' Share-based Compensation shows a peak YoY skyrocketed of 863.96% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Arcutis Biotherapeutics' Share-based Compensation stood at $7.9 million in 2020, then skyrocketed by 200.79% to $23.9 million in 2021, then skyrocketed by 36.79% to $32.7 million in 2022, then climbed by 18.76% to $38.8 million in 2023, then climbed by 7.52% to $41.7 million in 2024.